Zero Hedge reports on how the scheme works:
Shortly after the close - following its massive intraday surge on the back of what, at best, were extremely limited and extremely early results of its COVID-19 vaccine - Moderna has announced that it has commenced an underwritten public offering of $1.25 billion in shares of common stock.
Moderna expects to use the net proceeds of the offering to fund working capital needs related to the manufacturing of mRNA-1273, its vaccine candidate against the novel coronavirus (SARS-CoV-2), for distribution in the United States and outside the United States, assuming necessary regulatory approvals are obtained, and the remainder, if any, to fund clinical development and drug discovery in existing and new therapeutic areas; to fund further development of its mRNA technology platform and the creation of new modalities; or to fund working capital and other general corporate purposes.
Morgan Stanley is acting as sole book-running manager for the offering.
The shares are reportedly offered between $75 and $77.50 each, and MRNA shares are sliding after hours...
So MRNA manages to raise equity capital at a price 15-20% above its Friday close... Can anyone say "pump'n'dump"...
https://twitter.com/JTSEO9/status/1262479231226982401
And jumping quickly on the bandwagon, several other biotech stocks immediately offered shares in secondaries:
*KRYSTAL BIOTECH SHARES ARE SAID TO BE OFFERED AT $55 TO $56
*CLOVIS SHARES ARE SAID TO BE OFFERED AT $8.05 TO $8.50
*BELLEROPHON SHARES ARE SAID TO BE OFFERED AT $13 EACH
*NOVAVAX FILES TO SELL UP TO $250M OF SHARES
*HEXO ANNOUNCES PROPOSED OFFERING
This morning, drug company Moderna shouted from the mountaintops that the first study of its experimental COVID-19 vaccine candidate - a pre-clinical human trial - showed "promising results". But as analysts later pointed out, the details - for example, the study's focus was 'safety', and vaccine was only tested in two low doses on 8 patients.
Well, one twitter user @TESLACharts who has obtained a large following for their incisive tweets about Tesla (and other valuation-related absurdities) tweeted a surprisingly detailed explanation of why investors should take today's announcement with a massive grain of salt, and why - going forward - they should be wary of the company and any results from the trial, which is being carried out in partnership with NIAID.
As it turns out, not only has Moderna CEO Stephane Bancel (whose Moderna stake has made him a billionaire) been selling a surprising amount of Moderna stock, but a mysterious company called "Flagship Pioneer" that also happens to be Moderna's largest shareholder has been selling large blocks of shares as well. That company, as @TeslaCharts explains, is controlled by Bancel.
https://twitter.com/TESLAcharts/status/1262427914643083265
https://twitter.com/TESLAcharts/status/1262427916501233669
https://twitter.com/TESLAcharts/status/1262427919227461632
https://twitter.com/TESLAcharts/status/1262427921228214272
https://twitter.com/TESLAcharts/status/1262427923321163777
Though he's not well known to the wider public, Bancel was once compared to Elizabeth Holmes - and that was after the WSJ published its series of reports exposing Theranos as a fraud.
https://twitter.com/TESLAcharts/status/1262427925137285120
Another thing: Trump's own Vaccine Czar owns a large slug of Moderna call options. Some have called for him to sell them because of the obvious conflict. But the fact hasn't been widely discussed on Monday is surprising.
https://twitter.com/TESLAcharts/status/1262427926991196162
The Twitter user suspects that Bancel will continue selling tomorrow, guaranteeing that "whether or not his vaccine works" Bancel will be "quite rich either way."
https://twitter.com/TESLAcharts/status/1262427928501063680
Basically, while the results released today seemed to suggest that the vaccine can create COVID-19 antibodies in patients, there's still some doubt about how long COVID-19 antibodies can keep patient's immune, or whether COVID-19 might end up evolving like the flu, requiring repeated immunizations to maintain its protective effects. In other words, while this is indeed a promising development, whether or not the vaccine will ultimately be effective remains uncertain.
Via ZeroHedge.com
Mike Adams (aka the "Health Ranger") is the founding editor of NaturalNews.com, a best selling author (#1 best selling science book on Amazon.com called "Food Forensics"), an environmental scientist, a patent holder for a cesium radioactive isotope elimination invention, a multiple award winner for outstanding journalism, a science news publisher and influential commentator on topics ranging from science and medicine to culture and politics.
Mike Adams also serves as the lab science director of an internationally accredited (ISO 17025) analytical laboratory known as CWC Labs. There, he was awarded a Certificate of Excellence for achieving extremely high accuracy in the analysis of toxic elements in unknown water samples using ICP-MS instrumentation.
In his laboratory research, Adams has made numerous food safety breakthroughs such as revealing rice protein products imported from Asia to be contaminated with toxic heavy metals like lead, cadmium and tungsten. Adams was the first food science researcher to document high levels of tungsten in superfoods. He also discovered over 11 ppm lead in imported mangosteen powder, and led an industry-wide voluntary agreement to limit heavy metals in rice protein products.
Adams has also helped defend the rights of home gardeners and protect the medical freedom rights of parents. Adams is widely recognized to have made a remarkable global impact on issues like GMOs, vaccines, nutrition therapies, human consciousness.
Please contact us for more information.
